Drug Manufacturers - General · NYSE
Cours Actuel
$1008.33
AVANTAGE CONCURRENTIEL
↑Patent Protection on Key Drugs
Lilly benefits from strong patent protection on drugs like Trulicity and Mounjaro. This exclusivity allows for premium pricing and market share dominance before generics enter.
↑Established Brand Reputation in Diabetes Care
Lilly has cultivated a strong brand in diabetes, fostering physician and patient loyalty. This reputation provides a competitive edge in a growing market.
↑Pipeline of Innovative Therapies
Lilly's robust pipeline, particularly in Alzheimer's and obesity, offers future growth potential. Successful drug launches will further solidify their market position.
RISQUES D'INVESTISSEMENT
↓Patent Expirations and Generic Competition
Loss of exclusivity on key drugs will significantly impact revenue. Lilly must successfully launch new products to offset these losses and maintain growth.
↓Clinical Trial Failures and Regulatory Hurdles
Drug development is inherently risky, and clinical trial failures are common. Regulatory delays or rejections can significantly impact pipeline value.
↓Pricing Pressure and Reimbursement Challenges
Increasing pressure from payers to lower drug prices could erode profitability. Changes in reimbursement policies could limit access to Lilly's therapies.
Combinez les insights IA avec la valorisation DCF ou PE pour calculer la valeur intrinsèque. Prenez de meilleures décisions de valorisation avec des données.
Cette page fournit des insights de valorisation alimentés par IA pour Eli Lilly and Company (LLY), y compris l'avantage concurrentiel et les facteurs de risque d'investissement. La valorisation est centrale pour des décisions d'investissement saines — utilisez les outils de valorisation DCF et PE de MiniValuator avec ces insights IA pour calculer la valeur intrinsèque de LLY, la marge de sécurité, et arriver à une valorisation bien fondée.
